# Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma

> **NCT07733466** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peter Brett, MD** · enrollment: 20 (estimated)

## Conditions studied

- Betel-nut-associated Oral Carcinoma

## Interventions

- **DRUG:** Pembrolizumab and cetuximab

## Key facts

- **NCT ID:** NCT07733466
- **Lead sponsor:** Peter Brett, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2030-07
- **Final completion:** 2031-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733466, "Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*